Skip to main content
Equibles
BGLC logo

BGLC · BioNexus Gene Lab Corp

Track BGLC — free

Use BGLC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BGLC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.21 -0.02 (-1.86%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — cleared Aug 14, 2026

The latest filing states the doubt was alleviated.

“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. Management believes that the Company’s existing cash balance, together with its positive working capital position, will provide sufficient liquidity to fund operations and meet its obligations as they become due for at least the next twelve months from the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$3.53M
Shares
2.93M
Volume · Oct 20 1043 Avg daily vol (3M) 11.4K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.21 Open$1.23 Day$1.21–1.23 52W close$1.20–5.48 Avg vol 30d9K Short int10K · 0.3% float · 1.5d Short vol93% DataJan 2021–Oct 2026 Filing10-Q · Aug 14

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$3.13M
Trailing 12 months
Net income (TTM)
−$2.58M
Trailing 12 months
Revenue growth YoY
-96.6%
Year over year
Operating margin
-81.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-24.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.23M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+34.5%
Year over year · more shares
Price change (1Y)
-76.1%
Trailing year
Short interest
0.3%
Latest settlement · 1.5 days to cover
View all 122 metrics

Quarterly results

Revenue Net income Net loss
▲3% $2.63M −$1.35M '24 Q3 ▲11% $2.52M −$348,319 '24 Q4* ▼10.3% $2.14M −$623,327 '25 Q1 ▲14.5% $2.26M −$616,172 '25 Q2 ▼3.3% $2.54M −$708,991 '25 Q3 ▼80.8% $483,760 −$1.04M '25 Q4* ▼98.9% $22,842 −$543,575 '26 Q1 LATEST ▼96.6% $76,156 −$286,451 '26 Q2

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −43%
below
Price vs 50-day avg −16%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −17%
trailing
6-month return −44%
trailing
YTD return −69%
this year
Relative strength −53%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+50% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.34% of float · ▼ -22.4% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
3 holders — mid 3-yr range
Squeeze score 30
low risk · 0–100
Fundamentals
Fair
Revenue growth −22%
Y/Y
Gross margin 15%
expanding
EPS growth +46%
Y/Y
Free cash flow $-1.9M
Quant / Vol
risk profile
Very High
Volatility 68%
annualized · 1-yr
Max drawdown −78%
past year
ATR 7.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−43% Bearish
Price vs 50-day avg
−16% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+50% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.34% of float · ▼ -22.4% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
3 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $5
vs 200-day avg -43% vs 50-day avg -16%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Specialty Chemicals — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BGLC
BioNexus Gene Lab Corp
this stock
$3.53M -69.5% -21.9% — 0.3%
LIN
Linde PLC
 $232.08B +17.7% +3.0% 32.5 1.3%
AIQUF
L Air Liquide SA /Fi
 $123.29B +2.9% — — 0.0%
ECL
Ecolab Inc.
 $80.78B +9.8% +2.2% 38.7 1.9%
SHW
Sherwin Williams Co
 $80.50B +3.7% +2.1% 30.6 2.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
3
% held
0.5%
Net QoQ
+14.2K sh
Top holder
HRT FINANCIAL LP
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Falling
Shares short
10.1K
Days to cover
1.5d
Change
-2.9K sh
View
Short Volume
Short vol %
93%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
597
Value
$890
As of
Sep 24, 2026
View
Off-Exchange
Off-exchange %
61.9%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$7.4M
Net income (FY)
$-3.0M
EPS diluted
$-0.09
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 7, 2026
This year
10
View

Performance

5D 20D 120D MTD YTD
BGLC -8.7% -17.5% -44.5% -1.2% -69.5%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -7.6% -16.9% -52.6% -2.1% -82.3%
Key facts CIK 1737523 CUSIP 090628306 Visit website Investor relations